Q4 2023 Management View CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...

生物科技行业面临挑战，10X Genomics Inc (TXG)股价跌至52周新低，触及11.89美元。根据 InvestingPro 数据显示，技术指标表明该股票已处于超卖区域，公司保持着4.9的健康流动比率。这一最新价格水平凸显了公司股价的急剧下跌，过去一年累计下跌75.65%。投资者正在应对行业整体压力和公司特定不利因素的双重影响，导致持续抛售，最终使公司股价创下新低。这个52周低点清晰地 ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Investing.com -- 实验室工具设备行业的公司股票，包括Bruker、Illumina、Quanterix、Bio-Techne、10X Genomics和Qiagen，在盘前交易中出现下跌。这一下跌趋势是在美国国立卫生研究院（NIH）宣布计划通过降低研究机构向政府收取的最高间接成本率来大幅减少对医学研究人员的报销后出现的。

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other stocks in Cathie Wood’s portfolio. Cathie Wood is one of Wall Street’s most ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...